GlassScriptPhysician profile
Sunil K Shah
NPI 1275517211
$11,710.11
in general payments reported to CMS, 2019-2025
49 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,071 · 2020: $1,796 · 2021: $1,984 · 2022: $1,661 · 2023: $1,778 · 2024: $1,292 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,123 · Education: $75.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,122.72 |
| Education | $75.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,752.12 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,521.75 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Nestle Healthcare Nutrition INC. | $989.34 | 2020-2023 | |
| Abbvie INC. | $965.92 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Allergan, INC. | $803.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $581.15 | 2019-2024 | Verquvo, Steglatro |
| Otsuka America Pharmaceutical, INC. | $399.07 | 2022-2025 | Rexulti |
| Pfizer INC. | $387.42 | 2019-2025 | |
| Novo Nordisk INC | $382.96 | 2019-2025 | Ozempic, Rybelsus |
| Aimmune Therapeutics, INC. | $308.95 | 2024-2025 | Zenpep |
| Amarin Pharma, INC. | $298.98 | 2019-2022 | |
| Lilly USA, LLC | $274.17 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.45 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $229.06 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $221.94 | 2021-2025 | Eliquis, Camzyos, Cobenfy |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.